Abstract
In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.
| Original language | English |
|---|---|
| Pages (from-to) | 2019-2022 |
| Number of pages | 4 |
| Journal | European Journal of Cancer |
| Volume | 32 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Oct 1996 |
Fingerprint
Keywords
- Breast cancer
- Colorectal cancer
- EO9
- Gastric cancer
- Pancreatic cancer
- Phase II study
- Proteinuria
- Renal toxicity
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. / Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Ten Bokkel Huinink, W. W.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; Te Velde, A.; Lan, J.; Verweij, J.
In: European Journal of Cancer, Vol. 32, No. 11, 10.1996, p. 2019-2022.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
AU - Dirix, L. Y.
AU - Tonnesen, F.
AU - Cassidy, J.
AU - Epelbaum, R.
AU - Ten Bokkel Huinink, W. W.
AU - Pavlidis, N.
AU - Sorio, R.
AU - Gamucci, T.
AU - Wolff, I.
AU - Te Velde, A.
AU - Lan, J.
AU - Verweij, J.
PY - 1996/10
Y1 - 1996/10
N2 - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.
AB - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.
KW - Breast cancer
KW - Colorectal cancer
KW - EO9
KW - Gastric cancer
KW - Pancreatic cancer
KW - Phase II study
KW - Proteinuria
KW - Renal toxicity
UR - http://www.scopus.com/inward/record.url?scp=0030271681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030271681&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(96)00226-2
DO - 10.1016/0959-8049(96)00226-2
M3 - Article
VL - 32
SP - 2019
EP - 2022
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 11
ER -